Stock Update: AbbVie Inc (NYSE:ABBV) – Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival

[Reuters] – The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc’s newly approved hepatitis C treatment and, in most cases, will no longer . . . → Read More: Stock Update: AbbVie Inc (NYSE:ABBV) – Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival Similar Articles: Market Update (NASDAQ:ESRX): Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival Market Update: AbbVie Inc (NYSE:ABBV) – U.S. FDA approves AbbVie all-oral hepatitis C treatment Market Update: AbbVie Inc (NYSE:ABBV) – ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty